Symbols

LYRA(Delisted)

Lyra Therapeutics·NASDAQ

--(--)

5.52 / 10

Netural

Analyst coverage is limited to one neutral rating with a 33% historical win rate, reflecting weak consensus. Conversely, fund‑flow metrics are excellent (8.27/10) with positive inflows across all investor sizes, providing strong capital support.

Fund Flow Rating

Analyst RatingStrong Buy

Wall Street Opinions

Strong Buy

Buy

Hold

Sell

Strong Sell

Date2025-08-14

InstitutionHC Wainwright & Co.

Times predicted3

Historical Win Rate33.3%

Is money flowing into or out of LYRA?

LYRA holds a Bearish analyst rating, with 0% of experts assigning a Hold grade. Factoring in net Inflows from order flow data, the comprehensive Sentiment Score stands at 5.52/10 (Netural).